Company Overview
Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.
Recent News
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics
Amarantus to Present at 9th Annual LD Micro Invitational Conference
Stock Overview
Symbol
AMBS
Exchange
OTCPink
Shares OS
68,272,000
Market Cap
$1.37M
Last Price
$0.02
52-Week Range
$0.0151 - $0.0765
Fiscal Year End
December 31
Last Trade Time
06/19/2019 03:55 PM EDT
Investor Relations
American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com